The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Open accessAbstract
Chronic liver injury of different etiologies may result in hepatic fibrosis, a scar formation process consisting in altered deposition of extracellular matrix. Progression of fibrosis can lead to impaired liver architecture and function, resulting in cirrhosis and organ failure. Although fibrosis was previous thought to be an irreversible process, recent evidence convincingly demonstrated resolution of fibrosis in different organs when the cause of injury is removed. In the liver, due to its high regenerative ability, the extent of fibrosis regression and reversion to normal architecture is higher than in other tissues, even in advanced disease. The mechanisms of liver fibrosis resolution can be recapitulated in the following main points: removal of injurious factors causing chronic hepatic damage, elimination, or inactivation of myofibroblasts (through various cell fates, including apoptosis, senescence, and reprogramming), inactivation of inflammatory response and induction of anti-inflammatory/restorative pathways, and degradation of extracellular matrix. In this review, we will discuss the major cellular and molecular mechanisms underlying the regression of fibrosis/cirrhosis and the potential therapeutic approaches aimed at reversing the fibrogenic process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–238 of 238
Fang, X., Liu, L., Dong, J., Zhang, J., Song, H., Song, Y., Huang, Y., Cui, X., Lin, J., Chen, C., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14081 · Cited by 53
Kong, D., Zhang, F., Zhang, Z., Lu, Y., & Zheng, S. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.10.002 · Cited by 49
Park, S.-J., Sohn, H., Yoon, J., & Park, S. I. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.05.008 · Cited by 49
Epigenetic Changes during Hepatic Stellate Cell Activation
Götze, S., Schumacher, E. C., Kordes, C., & Häussinger, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128745 · Cited by 47
Yoon, Y., Fang, Z., Lee, J. E., Park, J. H., Ryu, J., Jung, K. H., & Hong, S. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.016 · Cited by 47
Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting
Singanayagam, A., & Triantafyllou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661182 · Cited by 47
Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview
Pinheiro, D., Dias, I., Ribeiro Silva, K., Stumbo, A. C., Thole, A., Cortez, E., de Carvalho, L., Weiskirchen, R., & Carvalho, S. (2019) · Cells · doi:10.3390/cells8111339 · Cited by 46
Identification of Diverse Lipid Droplet Targeting Motifs in the PNPLA Family of Triglyceride Lipases
Murugesan, S., Goldberg, E. B., Dou, E., & Brown, W. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064950 · Cited by 46
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Xing, Y., Zhao, T., Gao, X., & Wu, Y. (2016) · Scientific Reports · doi:10.1038/srep21309 · Cited by 45
Reversibility of liver fibrosis.
Brenner, D. A. (2013) · Europe PMC (PubMed Central) · Cited by 45
Regulation of the murine α2(I) collagen promoter by retinoic acid and retinoid X receptors
Wang, L., Rennie-Tankersley, L., Tang, M., Potter, J. J., & Mezey, E. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00058-9 · Cited by 44
Song, P., Zhang, J., Zhang, Y., Shu, Z., Xu, P., He, L., Yang, C., Zhang, J., Wang, H., Li, Y., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3315 · Cited by 44
Li, T., Yang, Y., Song, H., Li, H., Cui, A., Liu, Y., Su, L., Crispe, I. N., & Tu, Z. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.2a0118-031rr · Cited by 44
Antihepatic Fibrosis Drugs in Clinical Trials
Guo, Y., & Lu, L. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00023 · Cited by 41
Osawa, Y., Kojika, E., Hayashi, Y. K., Kimura, M., Nishikawa, K., Yoshio, S., Doi, H., Kanto, T., & Kimura, K. (2018) · Hepatology Communications · doi:10.1002/hep4.1158 · Cited by 38
Pietsch, V., Deterding, K., Attia, D. I., Ringe, K. I., Heidrich, B., Cornberg, M., Gebel, M., Manns, M. P., Wedemeyer, H. H., & Potthoff, A. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618786067 · Cited by 38
Watanabe, T. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.768 · Cited by 37
Binge Ethanol-Induced HDAC3 Down-RegulatesCpt1αExpression Leading to Hepatic Steatosis and Injury
Kirpich, I., Zhang, J., Gobejishvili, L., Kharebava, G., Barker, D. F., Ghare, S. S., Joshi‐Barve, S., McClain, C. J., & Barve, S. S. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12172 · Cited by 37
Genetic Diseases That Predispose to Early Liver Cirrhosis
Scorza, M., Elce, A., Zarrilli, F., Liguori, R., Amato, F., & Castaldo, G. (2014) · International Journal of Hepatology · doi:10.1155/2014/713754 · Cited by 36
Huang, Y., Chen, M., Guo, Q., Chen, Y., Zhang, L., Zhi-xin, C., & Wang, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8592 · Cited by 36
Ban, D., Hua, S., Zhang, W., Shen, C., Miao, X., & Liu, W. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0179-4 · Cited by 36
β-Catenin Regulates Mesenchymal Progenitor Cell Differentiation During Hepatogenesis
Berg, T., Langhe, S. D., Alam, D. A., Utley, S., Estrada, J. J., & Wang, K. S. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.10.033 · Cited by 35
Ding, D., Chen, L., Zhai, Y.-Z., Hou, C., Tao, L., Lu, S., Wu, J. H., & Liu, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-22662-6 · Cited by 32
Yang, J., Liu, Q., Cao, S., Xu, T., Li, X., Zhou, D., Pan, L., Li, C., Huang, C., Meng, X., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00980 · Cited by 31
Lee, H. S., Choi, J. H., Son, T., Wee, H., Bae, S., Seo, J. H., Park, J. H., Ryu, S. H., Lee, D., Jang, M. K., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0074-5 · Cited by 30
Cardoso, C. C., Matiollo, C., Pereira, C. H. J., Fonseca, J. S., Alves, H. E. L., da Silva, O. M., Menegassi, V. D. S., dos Santos, C. R., de Moraes, A. C. R., Schiavon, L. D. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85148-y · Cited by 28
Saito, S., Hata, K., Iwaisako, K., Yanagida, A., Takeiri, M., Tanaka, H., Kageyama, S., Hirao, H., Ikeda, K., Asagiri, M., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12140 · Cited by 25
Han, K., Zhang, Y., & Yang, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7207 · Cited by 24
Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease
Chancharoenthana, W., Leelahavanichkul, A., Taratummarat, S., Wongphoom, J., Tiranathanagul, K., & Eiam‐Ong, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187872 · Cited by 23
Zhang, J., WANG, M., ZHANG, Z., Luo, Z., Liu, F., & Liu, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3048 · Cited by 21
Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis
Vinaixa, C., Strasser, S. I., & Berenguer, M. (2017) · Transplantation · doi:10.1097/tp.0000000000001633 · Cited by 21
IL-22 inactivates hepatic stellate cells via downregulation of the TGF-β1/Notch signaling pathway
Chen, E., Cen, Y., Lu, D., Luo, W., & Jiang, H.-X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8516 · Cited by 21
Is This the Last Requiem for Simtuzumab?
Fickert, P. (2018) · Hepatology · doi:10.1002/hep.30309 · Cited by 19
Siegmund, S., Wojtalla, A., Schlosser, M., Schildberg, F. A., Knolle, P. A., Nüsing, R. M., Zimmer, A., Strassburg, C. P., & Singer, M. V. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.083 · Cited by 13
The liver X receptor in hepatic stellate cells: a novel antifibrogenic target?
Mallat, A., & Lotersztajn, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.018 · Cited by 11
Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis
Gentilini, A., Caligiuri, A., Provenzano, A., & Marra, F. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666161021163252 · Cited by 5
Self-citationWang, S., & Friedman, S. L. (2020) · Hepatology · doi:10.1002/hep.31151 · Cited by 2
Cited by
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis
Zhao, Y.-Q., Deng, X.-W., Xu, G.-Q., Lin, J., Lu, H.-Z., & Chen, J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1183808 · Cited by 71
Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives
Somnay, K., Wadgaonkar, P., Sridhar, N., Roshni, P., Rao, N., & Wadgaonkar, R. (2024) · Biomedicines · doi:10.3390/biomedicines12102229 · Cited by 70
Metadata
- Authors
- Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-10-15
- Volume
- 10
- Issue
- 10
- Pages
- 2759
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3206994391
- Cited by
- 270
- References
- 238
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.